Previous 10 | Next 10 |
RVT-3101 demonstrated improved efficacy results from the induction to chronic period in the TUSCANY-2 Phase 2b study in ulcerative colitis and was well tolerated with a favorable safety profile across all doses A Phase 2 study of RVT-3101 in Crohn’s disease has been initiated with to...
2023-06-27 11:38:29 ET Roivant Sciences ( NASDAQ: ROIV ) is scheduled to announce FQ4 earnings results on Wednesday, June 28th, before market open. The consensus EPS Estimate is -$0.32 (+17.9% Y/Y) and the consensus Revenue Estimate is $18.2M (+97.4% Y/Y). Over the las...
BASEL, Switzerland and LONDON and NEW YORK and BOSTON, June 26, 2023 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, June 28, 2023, to report its financial results for the fourth quarter and fis...
2023-06-22 11:41:01 ET Shares of U.K.-based biotech Roivant Sciences (NASDAQ: ROIV) were up by 10.2% on heavy volume as of 10:21 a.m. ET Thursday. The drugmaker's stock is jumping in response to positive long-term data for its midstage ulcerative colitis therapy, RVT-3101. RVT-3...
2023-06-22 08:32:13 ET Roivant Sciences ( NASDAQ: ROIV ) added ~12% pre-market Thursday after the U.K.-based biotech announced long-term data from a Phase 2b trial for its once-monthly subcutaneous therapy, RVT-3101, targeted at ulcerative colitis. Citing 56-week data from t...
This is the first-ever long-duration data reported for an anti-TL1A antibody At the expected Phase 3 once-monthly subcutaneous dose in the overall population, RVT-3101 treatment resulted in improved Clinical Remission 1 (36% at week 56 vs. 29% at week 14) and Endoscopic Improvement 2 ...
BASEL, Switzerland and LONDON and NEW YORK and BOSTON, June 21, 2023 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) today announced that it will host a live investor call and webcast at 8:00 AM ET on Thursday, June 22 to review results from the chronic period of TUSCANY-2, a large global Pha...
2023-06-13 04:32:53 ET Summary Ole Andreas Halvorsen's 13F stock portfolio value increased to $21.31B in Q1 2023, with Visa, McKesson, UnitedHealth, Elevance Health, and General Electric as the largest holdings. New stakes were established in Lululemon Athletica, Sherwin-Williams,...
2023-06-12 03:54:39 ET Summary Roivant Sciences exhibits a strong financial outlook, backed by its substantial cash position, strategic acquisitions, and efficient R&D expense management. The company's innovative drug pipeline includes the breakthrough product VTAMA for atopic...
2023-05-26 22:25:40 ET Summary Roivant Sciences recently won approval for a topical cream, VTAMA, that looks set to achieve blockbuster (>$1bn per annum) sales. The company has several other highly promising late-stage clinical assets with blockbuster potential, and multiple da...
News, Short Squeeze, Breakout and More Instantly...
Roivant Sciences Ltd. Company Name:
ROIV Stock Symbol:
NASDAQ Market:
Roivant Sciences Ltd. Website:
2024-07-11 10:45:04 ET Rivian Automotive Inc (RIVN) RIVN is trading UP for the last 5 days, and it at trading at $16.74 with volume of 18,885,597 and a one day change of $0.37 (2.23%). Rivian Automotive Inc has a 52-week low of 12.15 and a 52-week high of $32.60. The business's 50-d...
2024-06-02 17:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BASEL, Switzerland and LONDON and NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the fourth quarter and fiscal year ended March 31, 2024, and provided a business update. Once-daily brepocitinib produced the best Treatment Failure...